Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02278588 · ClinicalTrials.gov registry record

Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.

A clinical trial, sponsored by State University of New York at Buffalo.

Completed
Registry status
45
Enrollment target

NCT02278588: Completed study, sponsored by State University of New York at Buffalo.

NCT02278588 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02278588 has completed, sponsored by State University of New York at Buffalo.

COMPLETED
Registry status
45 participants
Enrollment target

Study Summary

In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy controls. Will also compare the changes in Mini-Mental State Exam (MMSE) and Montreal Cognitive Assessment (MoCA) scores and plasma brain-derived neurotrophic factor (BDNF) with changes in brain cognitive biomarkers in all IPD patients and HC over 2.5 years.

Interventions

  • DRUG Rasagiline

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2014-11
Est. Completion 2017-12

What the finished NCT02278588 record still lists

NCT02278588 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Rasagiline is the first listed.

NCT02278588 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02278588 about?

NCT02278588 is a clinical study titled "Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.". In this investigator-initiated study, we will compare changes in brain cognitive biomarkers assessed by diffusion tensor imaging over 2.5 years among 12 patients with Idiopathic Parkinson's disease (IPD) receiving rasagiline, 20 IPD patients not receiving MAO-B inhibitors and 25 age-matched healthy ...

What is the current status of trial NCT02278588?

This trial is currently completed. The enrollment target is 45 participants. The study started on 2014-11. Estimated completion is 2017-12.

What interventions are being tested in trial NCT02278588?

The interventions under investigation include: Rasagiline (DRUG).

Who is sponsoring clinical trial NCT02278588?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02278588, the US trial registry maintained by the National Library of Medicine. NCT02278588 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.